Transcode Therapeutics (RNAZ) Convertible Debt (2020 - 2021)

Transcode Therapeutics' (RNAZ) quarterly Convertible Debt came in at $2.1 million in Q2 2021, up 1.88% on a QoQ basis from $2.1 million in Q4 2020.

Transcode Therapeutics (RNAZ) Convertible Debt (2020 - 2021) Analysis & Trends

Transcode Therapeutics (RNAZ) has 2 years of Convertible Debt data on file, last reported at $2.1 million in Q2 2021.

Quarterly Convertible Debt changed N/A year-over-year to $2.1 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $2.1 million (changed N/A YoY) and the FY2020 annual result came in at $2.1 million, changed N/A from the prior year.
Convertible Debt improved to $2.1 million in Q2 2021, from $2.1 million in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $2.1 million in Q2 2021 to a low of $2.1 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.71 Bn	131.86 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.55 Bn	78.55 Bn	3.93 Bn
3	Argenx Se	65.26 Bn	60.07 Bn	1.37 Bn
4	Moderna	59.81 Bn	54.67 Bn	52.00 Mn
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.87 Bn	28.56 Bn	992.69 Mn
7	BioNTech SE	28.13 Bn	9.74 Bn	668.28 Mn
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn
9	Royalty Pharma	27.31 Bn	26.47 Bn	-
10	Transcode Therapeutics	2.82 Mn	2.82 Mn	-

Download Data

Date	Value
Jun 30, 2021	2.13 Mn
Dec 31, 2020	2.09 Mn